Madrid, January 27th, 2020.- PharmaMar (PHM:MSE) and Bionical Emas, a global specialist Clinical Research Organization (CRO) have today announced the launch of an Expanded Access Program (EAP) for lurbinectedin to … Continue reading “PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.”
vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce that enrolment into the pivotal European NOSTRA III (NO … Continue reading “vasopharm completes patient enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)”
LONDON, Jan. 28, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Piers Morgan, CFO of … Continue reading “Verona Pharma to Present at LSX World Congress 2020”
Madrid, January 27th, 2020.- PharmaMar (PHM:MSE) and Bionical Emas, a global specialist Clinical Research Organization (CRO) have today announced the launch of an Expanded Access Program (EAP) for lurbinectedin to … Continue reading “PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.”
Amsterdam, The Netherlands, January 23, 2020: iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces today the closing of a … Continue reading “iOnctura raises EUR 15 million in Series A financing to progress its pipeline into clinical development”
Acquisition of Consumer Healthcare company Easypharm OTC GmbH strengthens position in Consumer Healthcare Portfolio includes leading brands easysleep® and easyrelax® January 23, 2020 Neuraxpharm Group (Neuraxpharm), a leading European … Continue reading “European CNS specialist Neuraxpharm strengthens expansion into Austrian market with acquisition of easypharm”
The proceeds will be used to advance the first MKK4 inhibitor into clinical development later in 2020 Novo Seeds, the early stage investment and company creation team of Novo Holdings, … Continue reading “Novo Seeds Portfolio Company HepaRegeniX GmbH secures Series B Financing in excess of EUR 11 Million”
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces it has partnered with the Human Amyloid Imaging Conference (15-17 January 2020, Miami, USA) as … Continue reading “IXICO to Present Tau PET Imaging Research at Human Amyloid Imaging Conference”
Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function Clinically relevant secondary endpoints met, including progressive and statistically significant improvements in quality … Continue reading “Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy”
LONDON, Jan. 10, 2020 – Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces the appointments of Dr. Alex Jackson as Head of Research … Continue reading “Theragnostics Expands Team with Significant Appointments”
Strengthened BiOrigin Entrepreneur-in-residence Advisory Unit with seasoned CEOs REPAIR Impact investments now total USD 48 million in eight companies since its inception Significant progress with portfolio companies Successful Seed Summit … Continue reading “Novo Seeds Provides Business Update”
LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, will release results on Monday, January … Continue reading “Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy”
Creates a global leader with first in class molecules for fibrotic disease Galecto was first incubated by Novo Seeds and funded through the pre-seed grant program of the Novo Nordisk … Continue reading “Novo Seeds Portfolio Company Galecto Announces Merger with US based PharmAkea”
Creates a global leader with first in class molecules for fibrotic disease Galecto was first incubated by Novo Seeds and funded through the pre-seed grant program of the Novo Nordisk … Continue reading “Novo Seeds Portfolio Company Galecto Announces Merger with US based PharmAkea”
Key hires enhance management for next development phase 09 January 2020, Windsor, UK: Macrophage Pharma Limited (“MPL”), a biotech company focused on the discovery and development of next-generation immunomodulatory small molecules … Continue reading “Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer”
Expansion of Supervisory Board Supports Global Growth Strategy Amsterdam, Netherlands and Hoboken, New Jersey: January 8, 2020: Castor, a health-tech company that aims to leverage machine readable data to increase … Continue reading “Castor Appoints Dr. Ben Cons as Chairman of the Supervisory Board”
– Funds used to complete Phase 2b ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic Novo Seeds, the early stage investment and company creation team … Continue reading “Novo Seeds Portfolio Company NorthSea Therapeutics Raises USD 40 Million Series B Financing”
Syndicate includes leading UK investors Amadeus Capital Partners, Delin Ventures and Kindred Capital Appoints Jason C. Foster as Chief Executive Officer January 8, 2020, London, UK and Philadelphia, USA – Ori … Continue reading “Ori Biotech announces a $9.4M seed round to advance innovation in Cell and Gene Therapy manufacturing”
‒ The Fund has now committed a total of USD 48 million to eight companies ‒ REPAIR to adjust strategic scope for 2020 ‒ Global call for investment proposals will open during summer … Continue reading “Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines and provides strategic update”
To accelerate development of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – 17 December 2019 – Edinburgh Molecular Imaging Ltd (EMI), a company … Continue reading “Edinburgh Molecular Imaging Closes Financing”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com